PMID- 31364143
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 23
IP  - 14
DP  - 2019 Jul
TI  - Resveratrol alleviates osteoporosis through improving the osteogenic 
      differentiation of bone marrow mesenchymal stem cells.
PG  - 6352-6359
LID - 18459 [pii]
LID - 10.26355/eurrev_201907_18459 [doi]
AB  - OBJECTIVE: To investigate the protective effect of Resveratrol (RES) on 
      TNF-alpha-induced inhibition of osteogenic differentiation, thus alleviating the 
      progression of osteoporosis (OP). MATERIALS AND METHODS: OP model in rats was 
      first conducted by performing ovariectomy (OVX). Rats were randomly divided into 
      sham group, OVX group, and RES+OVX group. Body weight of each rat was regularly 
      recorded every week. Bone mineral density (BMD) of rat femoral metaphysis was 
      measured by micro-CT. Changes in radial degrees and loads of rat femora were 
      examined through three-point bending experiments. Relative levels of OCN and 
      Runx2 in each group were determined by quantitative Real Time-Polymerase Chain 
      Reaction (qRT-PCR). Alkaline phosphatase (ALP) activity and calcification ability 
      were assessed through ALP staining and alizarin red staining, respectively. Bone 
      mesenchymal stem cells (BMSCs) were extracted from healthy rats and divided into 
      control group, Tumor necrosis factor-alpha (TNF-alpha) group, RES group, and TNF-alpha+RES 
      group based on different treatments. Relative levels of OCN and Runx2, ALP 
      activity, and calcification ability in each group were detected in the same way. 
      Finally, protein levels of NF-kappaB and beta-catenin in BMSCs were determined. RESULTS: 
      Rats in each group gained body weight during the experimental period, especially 
      those in OVX group and RES+OVX group. No significant difference in the body 
      weight was found between OVX group and RES+OVX group. BMD in rat femora of 
      RES+OVX group was higher than in OVX group but lower than sham group. Elastic/max 
      radial degree and elastic/max load of femora were markedly reduced in OVX group 
      compared to RES+OVX group. Relative levels of OCN and Runx2, ALP activity and 
      calcification ability decreased in OVX group relative to sham group, which were 
      partially reversed by RES treatment. After osteogenic differentiation in BMSCs 
      induced with TNF-alpha, viability and calcification ability were markedly reduced and 
      were upregulated by RES treatment. Moreover, RES treatment enhanced the 
      downregulated levels of OCN and Runx2 in BMSCs undergoing TNF-alpha induction. 
      Upregulated protein levels of nuclear factor kappa-B (NF-kappaB) and beta-catenin in 
      TNF-alpha-induced BMSCs were downregulated by RES treatment. CONCLUSIONS: The 
      inhibited osteogenic differentiation of BMSCs undergoing TNF-alpha induction is 
      improved by resveratrol treatment, which contributes to alleviate the progression 
      of osteoporosis.
FAU - Chen, X-H
AU  - Chen XH
AD  - Department of Orthopedics, the Affiliated Hospital of Putian University; 
      Affiliated Hospital of Putian University Teaching Hospital of Fujian Medical 
      University; Affiliated Putian Hospital of Southern Medical University; Putian, 
      China. 1552279981@qq.com.
FAU - Shi, Z-G
AU  - Shi ZG
FAU - Lin, H-B
AU  - Lin HB
FAU - Wu, F
AU  - Wu F
FAU - Zheng, F
AU  - Zheng F
FAU - Wu, C-F
AU  - Wu CF
FAU - Huang, M-W
AU  - Huang MW
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Core Binding Factor Alpha 1 Subunit)
RN  - 0 (Runx2 protein, rat)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 104982-03-8 (Osteocalcin)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Alkaline Phosphatase/metabolism
MH  - Animals
MH  - Cell Differentiation/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Core Binding Factor Alpha 1 Subunit/genetics
MH  - Disease Models, Animal
MH  - Female
MH  - Mesenchymal Stem Cells/*cytology/drug effects/metabolism
MH  - Osteocalcin/genetics
MH  - Osteogenesis/*drug effects
MH  - Osteoporosis/diagnostic imaging/*drug therapy/etiology
MH  - Ovariectomy/adverse effects
MH  - Random Allocation
MH  - Rats
MH  - Resveratrol/*administration & dosage/pharmacology
MH  - Signal Transduction/drug effects
MH  - Tumor Necrosis Factor-alpha/*adverse effects
MH  - X-Ray Microtomography
EDAT- 2019/08/01 06:00
MHDA- 2020/10/02 06:00
CRDT- 2019/08/01 06:00
PHST- 2019/08/01 06:00 [entrez]
PHST- 2019/08/01 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 18459 [pii]
AID - 10.26355/eurrev_201907_18459 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6352-6359. doi: 
      10.26355/eurrev_201907_18459.